Beam Q3 2023: net loss $96.1M, Lilly deal up to $600M, pipeline on track

Beam Therapeutics Inc.

2023-Q3 EPS reported -$3.63 revenue$61,517,000

Net loss of $96.1M ($1.22 per share) vs $109.6M ($1.56) in Q3 2022; R&D $100M, G&A $25.4M.
Cash and securities $1.0B as of Sep 30, 2023; expected runway into H2 2026 with Lilly proceeds.
Lilly acquired opt-in rights to Verve's CV programs for $200M upfront + $50M equity + up to $350M milestones ($600M total).
BEAM-101 first patient treatment by year-end 2023; initial data on multiple patients in 2024.
BEAM-302 regulatory filing in Q1 2024; BEAM-301 IND in H1 2024; BEAM-201 initial data in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beam Therapeutics Inc. reported financial results for the third quarter 2023.

Period: the third quarter 2023
Result: reported results

Exact text from the filing

On November 8, 2023, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060660

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.